Evidence map›Paper›PMID 35208612›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.

Toshitaka Sawamura, Shigehiro Karashima, Ai Ohmori, Kei Sawada, Mitsuhiro Kometani, Yoshiyu Takeda, Takashi Yoneda

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Toshitaka SawamuraAsanogawa General Hospital, 83 Kosakamachi, Kanazawa 910-8621, Japan.ORCID 0000-0003-1279-4947
Shigehiro KarashimaDepartment of Health Promotion and Medicine of the Future, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan.
Ai OhmoriAsanogawa General Hospital, 83 Kosakamachi, Kanazawa 910-8621, Japan.
Kei SawadaAsanogawa General Hospital, 83 Kosakamachi, Kanazawa 910-8621, Japan.
Mitsuhiro KometaniDepartment of Endocrinology and Metabolism, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920-8641, Japan.
Yoshiyu TakedaAsanogawa General Hospital, 83 Kosakamachi, Kanazawa 910-8621, Japan.
Takashi YonedaDepartment of Endocrinology and Metabolism, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920-8641, Japan.ORCID 0000-0002-0921-158X
Kanazawa University · JPAsanogawa General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome is characterized by symmetrical polyarthritis and limb pitting edema. Although the detailed mechanisms of this syndrome have not been clearly understood, some agents including dipeptidyl peptidase-4 inhibitors have been reported to induce RS3PE syndrome. However, glucagon-like peptide-1 (GLP-1) analogues have not been reported to be associated with this syndrome. A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema. She was diagnosed with RS3PE syndrome. Oral prednisolone improved her symptoms. However, her symptoms worsened after the administration of dulaglutide, with elevated serum inflammatory markers. Discontinuation of dulaglutide without additional treatment improved her symptoms and laboratory findings. This case might indicate the possibility of development and worsening of RS3PE syndrome caused after GLP-1 analogue.

Indexed as

Immunoglobulin Fc FragmentsSynovitisAged, 80 and overEdemaFemaleGlucagon-Like PeptidesHumansRecombinant Fusion ProteinsdulaglutideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsdulaglutideGLP-1 analogueRS3PE syndrome

Identifiers

PMID35208612
PMCPMC8876704
OpenAlexW4212934772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.